Efficacy and safety of telitacicept in participants with Sjögren’s disease: Results from a multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study
By selecting “Yes,” you confirm that you are a U.S.-based healthcare professional and that you are accessing this site for scientific and medical information. This site is not intended for patients, caregivers, or non-U.S. audiences.